Get the Stockscreener App
10.56
7.04%
0.695
Surrozen Inc stock is traded at $10.56, with a volume of 23,329.
It is up +7.04% in the last 24 hours and up +18.71% over the past month.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
See More
Previous Close:
$9.87
Open:
$9.91
24h Volume:
23,329
Relative Volume:
0.72
Market Cap:
$34.33M
Revenue:
-
Net Income/Loss:
$-53.45M
P/E Ratio:
-8.8042
EPS:
-1.2
Net Cash Flow:
$-31.81M
1W Performance:
+7.26%
1M Performance:
+18.71%
6M Performance:
+5.23%
1Y Performance:
+32.39%
1-Day Range:
$9.69
$10.71
1-Week Range:
$9.50
$11.27
52-Week Range:
$5.9999
$16.19
Surrozen Inc Stock (SRZN) Company Profile
Name
Surrozen Inc
Sector
Industry
Phone
650-475-2820
Address
171 OYSTER POINT BLVD, SOUTH SAN FRANCISCO
Compare SRZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRZN
Surrozen Inc
|
10.56 | 34.33M | 0 | -53.45M | -31.81M | -21.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Surrozen Inc Stock (SRZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-11-21 | Initiated | BofA Securities | Buy |
| Sep-15-21 | Initiated | Guggenheim | Buy |
| Sep-07-21 | Initiated | Stifel | Buy |
Surrozen Inc Stock (SRZN) Latest News
Learn to Evaluate (SRZN) using the Charts - Stock Traders Daily
When the Price of (SRZN) Talks, People Listen - Stock Traders Daily
Companies Like Surrozen (NASDAQ:SRZN) Could Be Quite Risky - Simply Wall St
Contrasting Vigil Neuroscience (NASDAQ:VIGL) and Surrozen (NASDAQ:SRZN) - Defense World
(SRZN) Investment Analysis and Advice - Stock Traders Daily
Surrozen, Inc.: Q3 2024 Earnings Overview - TipRanks
Trading (SRZN) With Integrated Risk Controls - Stock Traders Daily
Alyeska Investment Group L.P. Expands Portfolio with Surrozen In - GuruFocus.com
Surrozen (NASDAQ:SRZN) Stock Price Down 7% – Here’s Why - Defense World
Stonepine Capital Management, LLC Increases Stake in Surrozen Inc - GuruFocus.com
Goldman Sachs Group Inc's Strategic Investment in Surrozen Inc - GuruFocus.com
Surrozen to Present at Upcoming Healthcare Investor Conferences - The Manila Times
Surrozen (SRZN) to Present at Guggenheim and Stifel Healthcare Conferences | SRZN Stock News - StockTitan
Surrozen Provides Third Quarter 2024 Financial Results and Business Update - ForexTV.com
(SRZN) Trading Signals - Stock Traders Daily
Surrozen partners with TCGFB for lung disease therapy By Investing.com - Investing.com Canada
Surrozen partners with TCGFB for lung disease therapy - Investing.com India
Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis - The Manila Times
The Column Group's biotech taps Surrozen for lung disease research pact - Fierce Biotech
StemPoint Capital LP Increases Stake in Surrozen Inc - GuruFocus.com
Trend Tracker for (SRZN) - Stock Traders Daily
Surrozen (NASDAQ:SRZN) Trading Up 4.3% – Here’s What Happened - Defense World
How To Trade (SRZN) - Stock Traders Daily
This Week's Bay Area Deal Sheet (October 10, 2024) - Bisnow
Surrozen extends South San Francisco headquarters lease By Investing.com - Investing.com Australia
Surrozen extends South San Francisco headquarters lease - Investing.com India
187,206 Shares in Surrozen, Inc. (NASDAQ:SRZN) Purchased by Nantahala Capital Management LLC - Defense World
Stonepine Capital Management LLC Invests $724,000 in Surrozen, Inc. (NASDAQ:SRZN) - Defense World
CVI Holdings LLC Makes New Investment in Surrozen, Inc. (NASDAQ:SRZN) - Defense World
Column Group LLC Makes New Investment in Surrozen, Inc. (NASDAQ:SRZNW) - Defense World
Boehringer Ingelheim to advance SZN-413 for retinal diseases - BioWorld Online
Patrick Brennan joins Selective Insurance as CFO - Reinsurance News
Surrozen and Boehringer Ingelheim advance SZN-413 development By Investing.com - Investing.com South Africa
Streamline Health CEO buys $1,008 in company stock By Investing.com - Investing.com UK
Selective Insurance appoints Patrick Brennan as chief financial officer - ROI-NJ.com
Surrozen and Boehringer Ingelheim advance SZN-413 development - Investing.com India
Surrozen earns $10M milestone payment in Retinal Diseases collaboration - TipRanks
Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration - GlobeNewswire
SThree Q3 net fees slip 8% amid challenging conditions - Staffing Industry Analysts
FINANCIALS: SThree reports 8% drop due to challenging conditions - Recruiter
Sagefield Capital LP Invests $2.35 Million in Surmodics, Inc. (NASDAQ:SRDX) - MarketBeat
Selective taps Progressive’s Brennan to fill CFO role on permanent basis - Re-Insurance.com
Recruiter SThree holds guidance despite ‘challenging’ market conditions - City A.M.
Selective lands Progressive’s Brennan as CFO, one year after Wilcox exit - Insurance Insider US
Selective Insurance Appoints Patrick S. Brennan as Chief Financial Officer - StockTitan
Plenham Limited statement: Jason Moseley - Bodyshop Magazine
Surrozen (NASDAQ:SRZN) Shares Up 2.4% - Defense World
(SRZN) Investment Analysis - Stock Traders Daily
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.60% - MSN
How to Take Advantage of moves in (SRZN) - Stock Traders Daily
Head to Head Comparison: 4D Molecular Therapeutics (NASDAQ:FDMT) vs. Surrozen (NASDAQ:SRZN) - Defense World
Surrozen Inc Stock (SRZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Surrozen Inc Stock (SRZN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| COLUMN GROUP III GP, LP | 10% Owner |
Apr 04 '24 |
Buy |
15.50 |
193,548 |
2,999,994 |
332,885 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):